Atherosclerosis: nexus of vascular dynamics and cellular cross talks

Dasagrandhi, Divya; Anusuyadevi, Muthuswamy; Swaminathan, Jayachandran Kesavan

doi:10.1007/s11010-021-04307-x

Cited by 11 publications

(8 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid retention and oxidation in the sub-endothelial region are crucial for the development of atherosclerotic plaques. 25 This was consistent with Zawada et al, 2016 hypothesis that atherosclerosis risk factors, like dyslipidemia, were linked to changes in monocyte subsets with a shift toward the intermediate monocytes. 26 A study by Xiang et al, 2020 observed that low serum HDL may induce upregulation of CD16 on monocytes, which may then result in an increase of intermediate monocytes in atherosclerosis patients.…”

Section: Discussionsupporting

confidence: 88%

Flow cytometry assessment of monocyte subsets alteration in hepatocellular carcinoma post hepatitis C virus infection

Ali

Hammad

Kotb

et al. 2022

EJI

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is assumed to be an immunogenic malignancy since 90% of cases develop in environments with ongoing inflammation. Monocyte subsets contribute to tumoral immunity. Most HCC patients are discovered at late stages, which lowers their survival chances. We aimed to determine whether altered frequency of monocyte subsets contribute to post hepatitis C virus infection-liver cirrhosis (HCV-LC) development to HCC. This cross-sectional study enrolled 105 patients classified as post HCV-HCC (n=72) and post HCV-LC (n=33) patients. The monocyte subsets frequency was assessed by flow-cytometry. There was a significant increase in intermediate monocytes and decrease in non-classical monocytes in HCC group when compared to the LC group (P = 0.001 and 0.006, respectively). Intermediate monocyte frequency was positively correlated with cholesterol and triglycerides (r = 0.296, P < 0.002 and r = 0.247, P < 0.011, respectively). The receiver operating characteristic (ROC) curve revealed that intermediate monocytes percentage at a cutoff ≥ 0.625% and non-classical monocytes percentage at a cutoff ≤ 0.61% differentiated between patients with HCV-LC and those with HCV-HCC with a sensitivity of 76.4% and 69.4%, respectively, while both revealed low specificity of 51.5%. According to logistic regression analysis, only the triglyceride level was found to be an independent risk factor for HCC development [OR =1.014 (11.001–1.026), P = 0.031]. Finally, we concluded that post-HCV-HCC is characterized by an upregulation of intermediate monocytes and a downregulation of non-classical monocytes when compared to Post-HCV-LC. Intermediate and non-classical monocytes frequency can aid to screening biomarkers for HCC development. Intermediate monocyte frequency may be linked to hyperlipemia. The level of triglycerides is proposed as an independent risk factor for HCC emergence.

show abstract

Section: Discussionsupporting

confidence: 88%

Flow cytometry assessment of monocyte subsets alteration in hepatocellular carcinoma post hepatitis C virus infection

Ali

Hammad

Kotb

et al. 2022

EJI

View full text Add to dashboard Cite

show abstract

“…Finally, the binding ability of different nanocarriers to activated endothelial cells was analyzed, as they play a key role in thrombosis. [ 31 ] Figure 2E showed that NT‐RGD/Pm had a stronger intracellular fluorescence signal (10 4 –10 5 ) on activated HUVEC, indicating that the adhesion of NT‐RGD/Pm to activated HUVEC was significantly higher than NT and NT‐RGD. For inactivated endothelial cells, the difference in capacity between NT‐RGD/Pm and the other two nanocarriers (NT and NT‐RGD) was less significant.…”

Section: Resultsmentioning

confidence: 99%

Platelet Membrane Cloaked Nanotubes to Accelerate Thrombolysis by Thrombus Clot‐Targeting and Penetration

Liu

Victorelli

Yuan

et al. 2022

Small

View full text Add to dashboard Cite

Thrombotic diseases have a high rate of mortality and disability, and pose a serious threat to global public health. Currently, most thrombolytic drugs especially protein drugs have a short blood‐circulation time, resulting in low thrombolytic efficiency. Therefore, a platelet membrane (Pm) cloaked nanotube (NT‐RGD/Pm) biomimetic delivery system with enhanced thrombolytic efficiency is designed. Nanotubes (NT) with an excellent clot‐penetration properties are used to load a protein thrombolytic drug urokinase (Uk). Platelet‐targeting arginine glycine‐aspartic peptide (RGD) is grafted onto the surface of the nanotubes (NT‐RGD) prior to cloaking. Multiple particle tracking (MPT) technique and confocal laser scanning microscope (CLSM) analysis are applied and the results show that the nanotubes possess a strong penetration and diffusion capacity in thrombus clots. After the Pm cloaking on NT‐RGD/Uk, it shows a thrombus microenvironmental responsive release property and the half‐life of Uk is six times longer than that of free Uk. Most importantly, NT‐RGD‐Uk/Pm exhibits a 60% thrombolytic efficiency in the FeCl3‐induced thrombosis mouse model, and it is able to significantly reduce the bleeding side effects of Uk. This Pm‐cloaked nanotube system is an effective and promising platform for the controlled and targeted delivery of drugs for the thrombus treatment.

show abstract

“…In the early pathological processes of hypertension and atherosclerosis, chronic vascular inflammation and toxic metabolic compounds of lipid oxidation lead to vascular endothelial dysfunction and lipid deposition ( Dasagrandhi et al, 2022 ). This process is accompanied by upregulation of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), and oxidized lipids and adhesion molecules mutually promote the plaque formation process of atherosclerosis ( Blankenberg et al, 2003 ; Malekmohammad et al, 2019 ).…”

Section: Antioxidant and Anti-inflammatory Effects And Molecular Mech...mentioning

confidence: 99%

Pharmacological properties, molecular mechanisms and therapeutic potential of ginsenoside Rg3 as an antioxidant and anti-inflammatory agent

et al. 2022

View full text Add to dashboard Cite

Inflammation and oxidative stress lead to various acute or chronic diseases, including pneumonia, liver and kidney injury, cardiovascular and cerebrovascular diseases, metabolic diseases, and cancer. Ginseng is a well-known and widely used ethnic medicine in Asian countries, and ginsenoside Rg3 is a saponin isolated from Panax ginseng C. A. Meyer, Panax notoginseng, or Panax quinquefolius L. This compound has a wide range of pharmacological properties, including antioxidant and anti-inflammatory activities, which have been evaluated in disease models of inflammation and oxidative stress. Rg3 can attenuate lung inflammation, prevent liver and kidney function damage, mitigate neuroinflammation, prevent cerebral and myocardial ischemia–reperfusion injury, and improve hypertension and diabetes symptoms. The multitarget, multipathway mechanisms of action of Rg3 have been gradually deciphered. This review summarizes the existing knowledge on the anti-inflammatory and antioxidant effects and underlying molecular mechanisms of ginsenoside Rg3, suggesting that ginsenoside Rg3 may be a promising candidate drug for the treatment of diseases with inflammatory and oxidative stress conditions.

show abstract

Atherosclerosis: nexus of vascular dynamics and cellular cross talks

Cited by 11 publications

References 111 publications

Flow cytometry assessment of monocyte subsets alteration in hepatocellular carcinoma post hepatitis C virus infection

Flow cytometry assessment of monocyte subsets alteration in hepatocellular carcinoma post hepatitis C virus infection

Platelet Membrane Cloaked Nanotubes to Accelerate Thrombolysis by Thrombus Clot‐Targeting and Penetration

Pharmacological properties, molecular mechanisms and therapeutic potential of ginsenoside Rg3 as an antioxidant and anti-inflammatory agent

Contact Info

Product

Resources

About